Gilead acquires CAR-T specialist Arcellx for $7.8bn

Here's the thing: Gilead just dropped a whopping $7.8 billion to acquire Arcellx, which is a big deal in the CAR-T therapy space. This acquisition isn't just about the cash; it's about adding a promising therapy for blood cancer that's on the verge of FDA approval. They're paying $115 per share, plus a potential bonus if sales hit $6 billion by 2029. Talk about a high-stakes bet!

Turns out, this move builds on a partnership that started back in 2022, where Gilead's Kite subsidiary was already collaborating with Arcellx on anito-cel, a CAR-T therapy aimed at treating multiple myeloma. The wild part? If approved, anito-cel could become a foundational treatment option for patients who have run out of other therapies. Gilead's CEO is pretty optimistic about its potential, saying it could reshape the treatment landscape.

Also, there's a trend here worth noting: while all current CAR-T therapies are delivered ex vivo, there's a growing interest in in vivo therapies, which some investors are calling the future of cell and gene therapy. Gilead's acquisition is part of a larger wave of M&A activity in this space, with other big players like Eli Lilly and Bristol Myers Squibb making similar moves. It's an exciting time to be in biotech!